Related Experiment Video
Updated: Aug 16, 2026
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Experimental study of thalidomide for treatment of murine hepatocellular carcinoma
Yi-ming Yang1, Gang-jun Du, Hai-hong Lin
1Department of Oncology, First Affiliated Hospital, Henan University, Kaifeng 475001, China. yangymch@sina.com
Objective:
To study the therapeutic effect of thalidomide (Tha) on murine hepatocellular carcinoma.
Methods:
In murine transplanted hepatoma model, thalidomide was administered intragastrically alone (200 mg/kg daily for 10 days) or in combination with doxorubicin. The antitumor activity of Tha was observed in solid and ascitic tumor models.
Results:
Tha induced significant growth inhibition of solid hepatoma without obvious toxicity on peripheral blood cells and lymphocyte proliferation. Although Tha alone had no effect on the survival of mice with ascitic tumor, it showed a synergistic antitumor activity in combination with doxorubicin (Dox) in both solid and ascitic tumor models. Moreover, Tha reduced Dox-induced cytopenia and immunosuppression. Histological analysis of Tha-treated tumors revealed remarkably enhanced tumor necrosis and lymphocyte infiltration on the edge of tumor tissues.
Conclusion:
Tha has definite therapeutic effect on murine hepatoma, and the combination with Dox shows an enhanced therapeutic potential.
